Guggenheim Capital’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $237K | Buy |
12,389
+1,235
| +11% | +$26.8K | ﹤0.01% | 1467 |
|
|
2025
Q4 | $245K | Buy |
11,154
+462
| +4% | +$8.34K | ﹤0.01% | 1614 |
|
|
2025
Q3 | $130K | Buy |
+10,692
| New | +$145K | ﹤0.01% | 1541 |
|
|
2025
Q1 | – | Sell |
-16,107
| Closed | -$580K | – | 1699 |
|
|
2024
Q4 | $580K | Buy |
16,107
+4,608
| +40% | +$156K | ﹤0.01% | 1204 |
|
|
2024
Q3 | $488K | Buy |
11,499
+599
| +5% | +$25.4K | ﹤0.01% | 1417 |
|
|
2024
Q2 | $439K | Buy |
10,900
+1,576
| +17% | +$65.7K | ﹤0.01% | 1493 |
|
|
2024
Q1 | $330K | Buy |
9,324
+78
| +0.8% | +$2.09K | ﹤0.01% | 1632 |
|
|
2023
Q4 | $273K | Buy |
+9,246
| New | +$192K | ﹤0.01% | 1711 |
|
|
2023
Q3 | – | Sell |
-9,190
| Closed | -$226K | – | 1916 |
|
|
2023
Q2 | $226K | Buy |
9,190
+3,291
| +56% | +$106K | ﹤0.01% | 1744 |
|
|
2023
Q1 | $240K | Buy |
+5,899
| New | +$244K | ﹤0.01% | 1746 |
|
|
2022
Q4 | – | Sell |
-7,583
| Closed | -$363K | – | 1987 |
|
|
2022
Q3 | $363K | Sell |
7,583
-2,513
| -25% | -$138K | ﹤0.01% | 1603 |
|
|
2022
Q2 | $598K | Sell |
10,096
-3,893
| -28% | -$320K | ﹤0.01% | 1489 |
|
|
2022
Q1 | $1.63M | Sell |
13,989
-9,350
| -40% | -$1.09M | 0.01% | 1117 |
|
|
2021
Q4 | $3.51M | Buy |
23,339
+9,092
| +64% | +$1.23M | 0.02% | 824 |
|
|
2021
Q3 | $1.7M | Buy |
14,247
+1,086
| +8% | +$120K | 0.01% | 1133 |
|
|
2021
Q2 | $1.28M | Sell |
13,161
-135
| -1% | -$12K | 0.01% | 1344 |
|
|
2021
Q1 | $1.17M | Sell |
13,296
-292
| -2% | -$27.1K | 0.01% | 1317 |
|
|
2020
Q4 | $1.3M | Sell |
13,588
-69
| -0.5% | -$7.11K | 0.01% | 1193 |
|
|
2020
Q3 | $1.55M | Sell |
13,657
-354
| -3% | -$37.2K | 0.01% | 1004 |
|
|
2020
Q2 | $1.39M | Buy |
14,011
+7,758
| +124% | +$619K | 0.01% | 1054 |
|
|
2020
Q1 | $402K | Buy |
6,253
+1,676
| +37% | +$117K | ﹤0.01% | 1448 |
|
|
2019
Q4 | $273K | Buy |
4,577
+854
| +23% | +$52.7K | ﹤0.01% | 1870 |
|
|
2019
Q3 | $220K | Sell |
3,723
-985
| -21% | -$62.9K | ﹤0.01% | 1977 |
|
|
2019
Q2 | $304K | Sell |
4,708
-1,315
| -22% | -$84.9K | ﹤0.01% | 1861 |
|
|
2019
Q1 | $382K | Sell |
6,023
-2,986
| -33% | -$157K | ﹤0.01% | 1801 |
|
|
2018
Q4 | $342K | Buy |
+9,009
| New | +$318K | ﹤0.01% | 1841 |
|
|
2018
Q2 | – | Sell |
-12,544
| Closed | -$62K | – | 2589 |
|
|
2018
Q1 | $62K | Buy |
+12,544
| New | +$40.4K | ﹤0.01% | 2695 |
|
|
2017
Q4 | – | Sell |
-1,650
| Closed | -$12K | – | 2807 |
|
|
2017
Q3 | $12K | Buy |
+1,650
| New | +$10.4K | ﹤0.01% | 2774 |
|
|
2016
Q2 | – | Sell |
-1,708
| Closed | -$148K | – | 2927 |
|
|
2016
Q1 | $148K | Buy |
1,708
+2
| +0.1% | +$175 | ﹤0.01% | 2728 |
|
|
2015
Q4 | $201K | Sell |
1,706
-81
| -5% | -$8.04K | ﹤0.01% | 2763 |
|
|
2015
Q3 | $158K | Sell |
1,787
-68
| -4% | -$7.92K | ﹤0.01% | 2767 |
|
|
2015
Q2 | $201K | Buy |
1,855
+743
| +67% | +$92.4K | ﹤0.01% | 2825 |
|
|
2015
Q1 | $140K | Buy |
+1,112
| New | +$145K | ﹤0.01% | 2832 |
|
Other funds holding TNDM
SC
VPM
ACH
VCM
GKIM
DCM
Guggenheim Capital's TNDM Position: Q1 2026 in Review
Guggenheim Capital increased its Tandem Diabetes Care (TNDM) stake by 11% in Q1 2026, buying an estimated $26.8K and bringing the position to 12,389 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #1467.
Guggenheim Capital first reported a position in TNDM in Q1 2015 and has held it in 33 quarters since. The position peaked at $3.51M in Q4 2021. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.
- Guggenheim Capital held 12,389 shares of Tandem Diabetes Care worth $237K as of Q1 2026.
- Guggenheim Capital bought 1,235 Tandem Diabetes Care shares in Q1 2026, an estimated $26.8K.
- Tandem Diabetes Care made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1467 holding.
- Guggenheim Capital first reported a position in Tandem Diabetes Care in Q1 2015 and has held it in 33 quarters since.
- Guggenheim Capital's Tandem Diabetes Care position peaked at $3.51M in Q4 2021.
- 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.
Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.